menu
    • menu
    [{"orgOrder":0,"company":"Siren Biotechnology","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"AAV Immuno-gene Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Siren Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Siren Biotechnology \/ CIRM","highestDevelopmentStatusID":"4","companyTruncated":"Siren Biotechnology \/ CIRM"},{"orgOrder":0,"company":"Siren Biotechnology","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"AAV-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Siren Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Siren Biotechnology \/ Siren Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Siren Biotechnology \/ Siren Biotechnology"},{"orgOrder":0,"company":"Siren Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"SRN-101","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Siren Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Siren Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Siren Biotechnology \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Siren Biotechnology

    Menu

    Siren Biotechnology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Siren Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Siren Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRN-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Siren’s SRN-101 Gains FDA Orphan and Rare Pediatric Status for High-Grade Gliomas

                            Details : SRN-101 is a recombinant adeno-associated viral (AAV) vector expressing an engineered cytokine, it is being investigated for the treatment of high-grade gliomas.

                            Brand Name : SRN-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 18, 2024

                            Lead Product(s) : SRN-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Siren Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Siren Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Catalent Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Siren Biotechnology and Catalent Partner to Manufacture AAV Gene Therapies for Cancer

                            Details : The partnership aims to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies, being developed for the treatment of cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 08, 2024

                            Lead Product(s) : AAV-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Catalent Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Siren Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Siren Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV Immuno-gene Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : CIRM

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM...

                            Details : The funding will support the development of novel AAV immuno-gene therapies for cancer, which exhibited potent anti-tumor effects in preclinical models of brain cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 01, 2023

                            Lead Product(s) : AAV Immuno-gene Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : CIRM

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth